Home Newsfeeds Baird Maintains Neutral on Silgan Hldgs, Raises Price Target to $53

Baird Maintains Neutral on Silgan Hldgs, Raises Price Target to $53

Baird analyst Ghansham Panjabi maintains Silgan Hldgs (NYSE:SLGN) with a Neutral and raises the price target from $50 to $53.

byBenzinga Newsdesk

January 26, 2023

1 minute read

Baird analyst Ghansham Panjabi maintains Silgan Hldgs (NYSE:SLGN) with a Neutral and raises the price target from $50 to $53.

French Drugmaker Sanofi Agrees To Buy Inhibrx’s Candidate For Rare Genetic Indication, For About $2.2B

By Vandana Singh

January 23, 9:00 AM

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.

INBX

Desktop Health Announces First Patients Treated With FDA-Cleared CMFlex – An Off-The-Shelf 3D Printed Synthetic Bone Graft Product Pioneered By Dimension Inx On The 3D-Bioplotter

By Benzinga Newsdesk

November 29, 5:31 PM

Chicago-based Dimension Inx, a regenerative therapeutics company, has now had its innovative CMFlex material implanted in multiple patientsCMFlex is an off-the-shelf, customizable bone graft material indicated for

Charles River Finalizes Agreement With CELLphenomics, Expanding 3D In Vitro Services For Cancer Therapy Drug Screening

By Benzinga Newsdesk

December 12, 9:11 AM

CELLphenomics' PD3D® tumor model platform will expand Charles River's portfolio of 3D in vitro testing servicesCharles River Laboratories International, Inc. (NYSE:CRL) today announced that it has entered into an

CRL

Why Bitcoin Will See One Last Dip Before Making ‘Explosive’ Move: Crypto Analyst Explains

By Mehab Qureshi

September 21, 8:38 AM

A pseudonymous crypto analyst on Wednesday said that Bitcoin (CRYPTO: BTC) will undergo one more market correction before making a massive move to the upside.

BTC

Baird Maintains Neutral on Silgan Hldgs, Raises Price Target to $53

Related Posts

French Drugmaker Sanofi Agrees To Buy Inhibrx’s Candidate For Rare Genetic Indication, For About $2.2B

Desktop Health Announces First Patients Treated With FDA-Cleared CMFlex – An Off-The-Shelf 3D Printed Synthetic Bone Graft Product Pioneered By Dimension Inx On The 3D-Bioplotter

Charles River Finalizes Agreement With CELLphenomics, Expanding 3D In Vitro Services For Cancer Therapy Drug Screening

Why Bitcoin Will See One Last Dip Before Making ‘Explosive’ Move: Crypto Analyst Explains